determin
feasibl
randomis
control
trial
rct
rhinothermi
common
cold
design
open
label
randomis
placebocontrol
feasibl
studi
set
singl
centr
research
institut
new
zealand
recruit
particip
commun
particip
adult
particip
symptom
common
cold
present
within
hour
onset
symptom
intervent
particip
randomli
assign
receiv
either
humidifi
air
c
via
high
flow
nasal
cannula
hfnc
two
hour
per
day
five
day
rhinothermi
vitamin
c
daili
five
day
control
proport
screen
candid
randomis
ci
potenti
particip
screen
elig
randomis
rhinothermi
well
toler
randomis
particip
complet
studi
ci
reduct
baselin
modifi
jackson
score
significantli
greater
rhinothermi
compar
control
day
maximum
differ
day
ci
substanti
clinic
benefit
threshold
modifi
jackson
score
unit
chang
conclus
studi
show
rct
rhinothermi
compar
vitamin
c
treatment
common
cold
feasibl
robust
adequ
power
rct
need
particularli
feasibl
studi
identifi
rhinothermi
improv
symptom
common
cold
compar
control
strength
limit
studi
first
studi
investig
use
rhinothermi
deliv
via
high
flow
nasal
cannula
treatment
common
cold
openlabel
randomis
placebocontrol
feasibl
studi
show
rct
rhinothermi
compar
vitamin
c
treatment
common
cold
feasibl
five
unit
chang
modifi
jackson
score
estim
repres
threshold
substanti
clinic
benefit
although
studi
show
clinic
statist
signific
benefit
rhinothermi
find
consid
caution
feasibl
studi
efficaci
primari
outcom
measur
robust
adequ
power
rct
need
particularli
feasibl
studi
identifi
rhinothermi
improv
symptom
common
cold
compar
control
steam
inhal
symptom
relief
tradit
remedi
common
cold
scientif
rational
treatment
hrv
temperatur
sensit
viru
temperaturedepend
reduct
viral
replic
studi
limit
includ
variabl
like
ineffect
method
deliv
heat
humid
air
high
flow
upper
airway
method
includ
deliveri
nozzl
held
distanc
away
nare
vent
anaesthet
mask
report
intervent
durat
also
variabl
cochran
review
assess
current
evid
could
support
refut
effect
recommend
need
robustli
design
adequ
power
randomis
control
trial
rct
assess
effect
rhinothermi
treat
common
cold
report
toler
studi
found
high
flow
nasal
cannula
devic
myairvo
fisher
paykel
healthcar
ltd
auckland
new
zealand
modifi
deliv
high
flow
humidifi
air
via
wide
bore
nasal
cannula
well
toler
healthi
volunt
potenti
advantag
devic
rhinothermi
deliv
consist
temperatur
humid
flow
rate
direct
upper
airway
studi
report
feasibl
studi
rhinothermi
treatment
common
cold
inform
design
robust
rct
treatment
specif
aim
feasibl
studi
estim
proport
potenti
particip
screen
undergo
randomis
complet
studi
turn
provid
estim
time
resourc
requir
undertak
rct
particip
request
complet
symptom
diari
everi
day
day
diari
compris
daili
modifi
jackson
score
questionnair
box
tick
first
felt
lot
better
compar
studi
entri
mean
chang
modifi
jackson
score
particip
felt
lot
better
use
estim
mcid
particip
return
clinic
second
final
visit
day
return
symptom
diari
particip
use
myairvo
return
devic
ask
fill
toler
questionnair
experi
nine
question
particip
record
answer
continu
scale
posit
least
posit
question
teach
session
connect
compon
clean
process
level
comfort
amount
moistur
devic
weight
nasal
interfac
noisi
appli
remov
nasal
interfac
likelihood
reus
futur
complianc
data
myairvo
upload
analys
primari
outcom
measur
proport
recruit
randomis
outcom
measur
includ
proport
randomis
particip
complet
studi
ii
mean
sd
modifi
jackson
score
randomis
day
initi
randomis
regimen
iii
time
feel
lot
better
compar
studi
entri
iv
time
sampl
size
chosen
assess
proport
screen
particip
randomis
trial
minimum
patient
approach
assum
recruit
rate
less
achiev
particip
particip
power
one
side
alpha
rule
recruit
rate
less
estim
sd
chang
baselin
modifi
jackson
score
sampl
size
least
accept
precis
estim
sd
base
chisquar
distribut
recruit
complet
rate
confid
interv
estim
clopperpearson
exact
method
mix
linear
model
exponentialintim
covari
matrix
use
estim
differ
modifi
jackson
score
treatment
time
post
hoc
interact
term
test
respons
differ
whether
nasal
swab
result
posit
confid
interv
sd
chang
baselin
modifi
jackson
score
estim
use
chisquar
distribut
logist
regress
use
estim
receiv
oper
characterist
curv
probabl
particip
say
better
compar
chang
baselin
modifi
jackson
score
time
measur
chosen
half
particip
report
improv
time
point
individu
sensit
specif
calcul
chang
baselin
modifi
jackson
score
time
surviv
analysi
use
estim
relationship
treatment
time
particip
said
felt
better
time
modifi
jackson
score
zero
particip
flow
studi
shown
figur
potenti
particip
screen
elig
particip
randomis
particip
complet
visit
may
juli
particip
predominantli
young
adult
nonsmok
tabl
recruit
rate
ci
one
main
reason
exclus
particip
symptom
hour
longer
present
figur
randomis
particip
complet
studi
result
retent
rate
lower
confid
limit
particip
symptom
mean
hour
present
time
mean
modifi
jackson
score
tabl
particip
complet
modifi
jackson
score
ten
day
tabl
show
mean
sd
median
iqr
rang
modifi
jackson
score
baselin
day
group
mean
chang
modifi
jackson
score
baselin
greater
rhinothermi
group
control
group
hour
remain
significantli
greater
control
group
day
tabl
figur
show
plot
chang
baselin
modifi
jackson
score
total
particip
report
feel
lot
better
within
day
randomis
particip
rhinothermi
group
control
group
particip
two
particip
fill
modifi
jackson
score
day
felt
lot
better
therefor
estim
mcid
use
score
particip
rhinothermi
group
nine
control
group
recognis
posthoc
threshold
lot
better
correspond
estim
substanti
clinic
benefit
rather
mcid
estim
chang
repres
substanti
clinic
benefit
chang
baselin
modifi
jackson
score
best
sensit
specif
particip
state
felt
lot
better
unit
modifi
jackson
score
day
differ
modifi
jackson
score
rhinothermi
group
control
group
greater
substanti
clinic
benefit
threshold
day
three
four
five
p
tabl
complet
resolut
symptom
denot
modifi
jackson
score
zero
occur
particip
within
day
randomis
hazard
ratio
ci
feel
lot
better
rhinothermi
compar
control
favour
rhinothermi
group
kaplanmei
base
surviv
curv
shown
figur
report
advers
event
estim
sd
modifi
jackson
score
sd
modifi
jackson
score
day
base
pool
valu
test
ci
chang
baselin
modifi
jackson
score
ci
nasal
swab
viral
pcr
result
posit
nasal
swab
pcr
respiratori
viru
found
particip
organ
found
shown
tabl
human
rhinoviru
commonli
detect
viru
found
one
third
particip
evid
interact
treatment
differ
modifi
jackson
score
nasal
swab
posit
neg
mean
total
use
myairvo
devic
hour
mean
sd
hour
per
day
eight
particip
use
myairvo
devic
day
seven
particip
use
less
day
day
myairvo
use
mean
sd
use
studi
shown
rct
rhinothermi
via
high
flow
nasal
cannula
treatment
common
cold
feasibl
studi
fulli
recruit
particip
within
eight
week
period
complet
studi
adher
rhinothermi
treatment
good
particip
symptomat
although
primari
outcom
studi
rhinothermi
modifi
myairvo
devic
associ
clinic
signific
reduct
common
cold
symptom
compar
treatment
vitamin
c
first
studi
investig
rhinothermi
use
modifi
myairvo
devic
strength
includ
randomis
control
design
complet
followup
particip
addit
use
realworld
control
treatment
increas
extern
valid
result
twothird
peopl
suffer
common
cold
buy
counter
product
symptom
relief
despit
inadequ
evid
effect
particip
studi
recruit
primarili
social
media
result
generalis
peopl
commun
symptom
common
cold
three
main
limit
appli
result
firstli
studi
design
feasibl
studi
mean
although
modifi
jackson
score
efficaci
outcom
measur
formal
prespecifi
primari
outcom
measur
secondli
due
natur
intervent
unabl
blind
particip
investig
alloc
intervent
futur
studi
aim
replic
result
explor
option
sham
rhinothermi
final
small
sampl
size
mean
although
studi
show
clinic
statist
signific
result
consid
rel
fragil
modifi
jackson
score
would
need
chang
small
number
particip
receiv
rhinothermi
intervent
match
placebo
group
conclus
differ
formal
fragil
index
calcul
chang
modifi
jackson
particip
use
myairvo
devic
two
hour
per
day
averag
throughout
day
treatment
period
hour
day
use
instruct
particip
use
devic
late
treatment
cours
symptom
improv
around
third
particip
reduc
flow
rate
suggest
give
particip
option
reduc
flow
initi
lower
start
flow
worthwhil
differ
randomis
group
observ
within
hour
efficaci
singl
dose
regimen
session
two
three
day
period
may
enhanc
implement
clinic
practic
worth
studi
howev
altern
rhinothermi
regimen
need
assess
studi
find
suggest
regimen
use
feasibl
studi
also
use
futur
rct
studi
also
inform
term
like
number
particip
requir
rct
estim
chang
modifi
jackson
score
denot
substanti
clinic
benefit
five
unit
chang
base
largest
sd
upper
ci
jackson
score
day
sampl
size
per
arm
would
give
power
alpha
detect
differ
symptom
score
equal
substanti
clinic
benefit
day
assum
drop
rate
deriv
lower
confid
interv
estim
would
requir
total
particip
rct
investig
three
randomis
treatment
compris
current
rhinothermi
regimen
sham
rhinothermi
regimen
vitamin
c
specif
respiratori
viru
identifi
pcr
particip
major
rhinoviru
respiratori
viru
detect
rate
compar
previou
studi
report
detect
rate
found
differ
treatment
effect
particip
nasal
swab
pcr
posit
neg
indic
find
generalis
symptomat
common
cold
restrict
posit
viru
detect
also
suggest
efficaci
may
also
relat
nontemperatur
relat
viral
effect
humidif
airway
enhanc
mucociliari
clearanc
studi
show
rct
rhinothermi
modifi
myairvo
devic
feasibl
rhinothermi
well
toler
estim
chang
denot
substanti
clinic
benefit
modifi
jackson
score
five
unit
chang
compar
vitamin
c
rhinothermi
improv
symptom
common
cold
least
substanti
clinic
benefit
threshold
day
efficaci
find
requir
replic
larger
studi
common
cold
investig
efficaci
rhinothermi
treatment
influenza
also
prioriti
view
temperaturesensit
influenza
virus
result
ci
potenti
particip
screen
elig
randomis
rhinothermi
well
toler
randomis
particip
complet
studi
ci
reduct
baselin
modifi
jackson
score
significantli
greater
rhinothermi
compar
control
day
maximum
differ
day
ci
substanti
clinic
benefit
threshold
modifi
jackson
score
unit
chang
conclus
studi
show
rct
rhinothermi
compar
lowdos
vitamin
c
treatment
common
cold
feasibl
robust
adequ
power
rct
need
particularli
feasibl
studi
identifi
rhinothermi
improv
symptom
common
cold
compar
control
first
studi
investig
use
rhinothermi
deliv
via
high
flow
nasal
cannula
treatment
common
cold
openlabel
randomis
control
feasibl
studi
show
rct
rhinothermi
compar
lowdos
vitamin
c
treatment
common
cold
feasibl
five
unit
chang
modifi
jackson
score
estim
repres
threshold
substanti
clinic
benefit
although
studi
show
clinic
statist
signific
benefit
rhinothermi
find
consid
caution
feasibl
studi
efficaci
primari
outcom
measur
common
cold
frequent
infect
worldwid
adult
report
two
four
cold
year
children
six
eight
cold
year
median
incub
period
depend
viru
usual
one
six
day
sever
symptom
typic
peak
two
three
day
symptom
onset
almost
alway
selflimit
ill
total
symptom
durat
seven
day
volunt
potenti
advantag
devic
rhinothermi
deliv
consist
temperatur
humid
flow
rate
direct
upper
airway
studi
report
feasibl
studi
rhinothermi
treatment
common
cold
inform
design
robust
rct
treatment
specif
aim
feasibl
studi
estim
proport
potenti
particip
screen
undergo
randomis
complet
studi
turn
provid
estim
time
resourc
requir
undertak
rct
estim
standard
deviat
sd
propos
primari
outcom
variabl
rct
modifi
jackson
score
sampl
size
rct
better
estim
estim
like
minimum
clinic
import
differ
mcid
modifi
jackson
score
among
peopl
common
cold
elig
take
part
studi
particip
elig
year
old
common
cold
symptom
less
hour
time
randomis
modifi
jackson
score
modifi
jackson
score
calcul
symptom
sever
questionnair
consist
eight
symptom
sneez
nasal
discharg
nasal
congest
sorescratchi
throat
cough
headach
malais
feverchil
score
scale
absent
mild
moder
sever
total
score
rang
particip
recruit
immunosuppress
medic
condit
andor
prescrib
immunosuppress
medic
diagnosi
asthma
copd
signific
respiratori
condit
nasal
condit
deviat
septum
chronic
rhiniti
could
impair
nasal
breath
use
cold
remedi
eg
decongestantscough
linctusthroat
lozeng
within
hour
randomis
current
use
antibiot
inhal
medic
known
allergi
ascorb
acid
vitamin
c
investig
believ
particip
care
giver
would
unabl
safe
use
myairvo
devic
without
medic
supervis
condit
investig
discret
believ
may
present
safeti
risk
impact
feasibl
studi
studi
result
paykel
healthcar
new
zealand
manufactur
myairvo
devic
written
inform
consent
obtain
start
studi
specif
procedur
studi
particip
abl
stop
intervent
time
without
withdrawn
studi
particip
also
abl
withdraw
studi
time
without
give
reason
particip
randomli
assign
ratio
two
group
receiv
either
rhinothermi
via
modifi
myairvo
devic
two
hour
per
day
five
day
control
medic
vitamin
c
healtheri
vitaco
health
nz
ltd
auckland
new
zealand
daili
five
day
randomis
schedul
comput
gener
studi
statistician
involv
studi
recruit
procedur
data
collect
train
myairvo
setup
use
particip
given
modifi
myairvo
devic
use
home
accord
regimen
humid
c
minut
five
day
depend
resolut
symptom
particip
encourag
use
devic
least
two
hour
per
day
longer
desir
either
singl
repeat
administr
prefer
even
particip
allow
reduc
flow
accord
comfort
home
three
day
particip
randomis
myairvo
group
contact
phone
check
advers
event
andor
problem
use
myairvo
particip
alloc
control
group
receiv
first
vitamin
c
tablet
ctu
randomis
home
four
day
lowdos
vitamin
c
use
control
therapeut
use
vitamin
c
symptom
develop
shown
consist
reduc
durat
cold
improv
cold
symptom
particip
expect
deriv
benefit
obtain
placebo
effect
low
dose
vitamin
c
use
studi
freeli
avail
pharmaci
new
zealand
unlik
benefit
taken
symptom
develop
oppos
regular
supplement
particip
use
vitamin
c
return
bottl
medicin
reconcili
particip
request
complet
symptom
diari
everi
day
day
diari
compris
daili
modifi
jackson
score
questionnair
box
tick
first
felt
lot
better
compar
studi
entri
mean
chang
modifi
jackson
score
particip
felt
lot
better
use
estim
mcid
assess
proport
screen
particip
randomis
trial
minimum
patient
approach
assum
recruit
rate
less
achiev
particip
particip
power
one
side
alpha
rule
recruit
rate
less
particip
flow
studi
shown
figur
potenti
particip
screen
elig
particip
randomis
particip
complet
visit
may
juli
particip
predominantli
young
adult
nonsmok
tabl
recruit
rate
ci
one
main
reason
exclus
particip
symptom
hour
longer
present
figur
randomis
particip
complet
studi
result
retent
rate
lower
confid
limit
particip
symptom
mean
hour
present
time
mean
modifi
jackson
score
tabl
particip
complet
modifi
jackson
score
ten
day
tabl
show
mean
sd
median
iqr
rang
modifi
jackson
score
baselin
day
group
mean
chang
modifi
jackson
score
baselin
greater
rhinothermi
group
control
group
hour
remain
significantli
greater
control
group
day
tabl
total
particip
report
feel
lot
better
within
day
randomis
particip
rhinothermi
group
control
group
particip
two
particip
fill
modifi
jackson
score
day
felt
lot
better
therefor
estim
mcid
use
score
particip
rhinothermi
group
nine
control
group
recognis
posthoc
threshold
lot
better
correspond
estim
substanti
clinic
benefit
rather
mcid
estim
chang
repres
substanti
clinic
benefit
chang
baselin
modifi
jackson
score
best
sensit
specif
particip
state
felt
lot
better
unit
modifi
jackson
score
day
differ
modifi
jackson
score
rhinothermi
group
control
group
greater
substanti
clinic
benefit
threshold
day
three
four
five
p
tabl
complet
resolut
symptom
denot
modifi
jackson
score
zero
occur
particip
within
day
randomis
particip
complet
modifi
jackson
score
day
rhinothermi
group
two
vitamin
c
group
hazard
ratio
ci
feel
lot
better
rhinothermi
compar
control
sd
modifi
jackson
score
day
base
pool
valu
test
ci
chang
baselin
modifi
jackson
score
ci
posit
nasal
swab
pcr
respiratori
viru
found
particip
organ
found
shown
tabl
human
rhinoviru
commonli
detect
viru
found
one
third
particip
evid
interact
treatment
differ
modifi
jackson
score
nasal
swab
posit
neg
time
point
studi
shown
rct
rhinothermi
via
high
flow
nasal
cannula
treatment
common
cold
feasibl
studi
fulli
recruit
particip
within
eight
week
period
complet
studi
adher
rhinothermi
treatment
good
particip
symptomat
although
primari
outcom
studi
particip
establish
common
cold
symptom
rhinothermi
modifi
myairvo
devic
associ
clinic
import
reduct
common
cold
symptom
compar
treatment
lowdos
vitamin
c
first
studi
investig
rhinothermi
use
modifi
myairvo
devic
strength
includ
randomis
control
design
complet
followup
particip
particip
studi
recruit
primarili
social
media
result
generalis
peopl
commun
symptom
common
cold
three
main
limit
appli
result
firstli
studi
design
feasibl
studi
mean
although
modifi
jackson
score
prespecifi
efficaci
outcom
measur
formal
specifi
primari
outcom
measur
secondli
due
natur
intervent
unabl
blind
particip
investig
alloc
intervent
futur
studi
aim
replic
result
explor
option
sham
rhinothermi
final
small
sampl
size
mean
although
studi
show
clinic
statist
signific
result
consid
rel
fragil
modifi
jackson
score
would
need
chang
small
number
particip
receiv
rhinothermi
intervent
match
control
group
conclus
differ
formal
fragil
index
calcul
chang
modifi
jackson
score
dichotom
variabl
complet
followup
particip
help
protect
fragil
howev
due
limit
larger
replic
studi
requir
particip
use
myairvo
devic
two
hour
per
day
averag
throughout
day
treatment
period
hour
day
use
instruct
particip
use
devic
late
treatment
cours
symptom
improv
around
third
particip
reduc
flow
rate
suggest
give
particip
option
reduc
flow
initi
lower
start
flow
worthwhil
differ
randomis
group
observ
within
hour
efficaci
singl
dose
regimen
session
two
three
day
period
may
enhanc
implement
clinic
practic
worth
studi
howev
altern
rhinothermi
regimen
need
assess
studi
find
suggest
regimen
use
feasibl
studi
also
use
futur
rct
studi
also
inform
term
like
number
particip
requir
rct
estim
chang
modifi
jackson
score
denot
substanti
studi
show
rct
rhinothermi
modifi
myairvo
devic
feasibl
rhinothermi
well
toler
estim
chang
denot
substanti
clinic
benefit
modifi
jackson
score
five
unit
chang
compar
low
dose
vitamin
c
establish
common
cold
rhinothermi
improv
symptom
least
substanti
clinic
benefit
threshold
day
efficaci
find
requir
replic
larger
studi
common
cold
investig
efficaci
rhinothermi
treatment
influenza
also
prioriti
view
temperaturesensit
influenza
virus
result
ci
potenti
particip
screen
elig
randomis
rhinothermi
well
toler
randomis
particip
complet
studi
ci
reduct
baselin
modifi
jackson
score
greater
rhinothermi
compar
control
day
maximum
differ
day
ci
substanti
clinic
benefit
threshold
modifi
jackson
score
unit
chang
openlabel
randomis
control
feasibl
studi
show
rct
rhinothermi
compar
lowdos
vitamin
c
treatment
common
cold
feasibl
five
unit
chang
modifi
jackson
score
estim
repres
threshold
substanti
clinic
benefit
although
studi
suggest
benefit
rhinothermi
find
consid
caution
feasibl
studi
efficaci
primari
outcom
measur
robust
adequ
power
rct
need
particularli
feasibl
studi
identifi
rhinothermi
improv
symptom
common
cold
compar
control
report
toler
studi
found
high
flow
nasal
cannula
devic
myairvo
fisher
paykel
healthcar
ltd
auckland
new
zealand
modifi
deliv
high
flow
humidifi
air
via
wide
bore
nasal
cannula
well
toler
healthi
volunt
potenti
advantag
devic
rhinothermi
deliv
consist
temperatur
humid
flow
rate
direct
upper
airway
studi
report
feasibl
studi
rhinothermi
treatment
common
cold
inform
design
robust
rct
treatment
specif
aim
feasibl
studi
estim
proport
potenti
particip
screen
undergo
randomis
complet
studi
turn
provid
estim
time
resourc
requir
undertak
rct
believ
particip
care
giver
would
unabl
safe
use
myairvo
devic
without
medic
supervis
condit
investig
discret
believ
may
present
safeti
risk
impact
feasibl
studi
studi
result
studi
approv
northern
b
ethic
health
disabl
ethic
committe
new
zealand
prospect
regist
australian
new
zealand
clinic
trial
registri
trial
id
studi
sponsor
fisher
paykel
healthcar
new
zealand
manufactur
myairvo
devic
written
inform
consent
obtain
start
studi
specif
procedur
studi
particip
abl
stop
intervent
time
without
withdrawn
studi
particip
also
abl
withdraw
studi
time
without
give
reason
particip
randomli
assign
ratio
two
group
receiv
either
rhinothermi
via
modifi
myairvo
devic
two
hour
per
day
five
day
control
medic
vitamin
c
healtheri
vitaco
health
nz
ltd
auckland
new
zealand
daili
five
day
randomis
schedul
comput
gener
studi
statistician
involv
studi
recruit
procedur
data
collect
particip
alloc
control
group
receiv
first
vitamin
c
tablet
ctu
randomis
home
four
day
lowdos
vitamin
c
use
control
therapeut
use
vitamin
c
symptom
develop
shown
consist
reduc
durat
cold
improv
cold
symptom
particip
expect
deriv
benefit
obtain
placebo
effect
low
dose
vitamin
c
use
studi
freeli
avail
pharmaci
new
zealand
unlik
benefit
taken
symptom
develop
oppos
regular
supplement
particip
use
vitamin
c
return
bottl
medicin
reconcili
particip
request
complet
symptom
diari
everi
day
day
diari
compris
daili
modifi
jackson
score
questionnair
box
tick
first
felt
lot
better
compar
studi
entri
mean
chang
modifi
jackson
score
particip
felt
lot
better
use
estim
mcid
particip
symptom
mean
hour
present
time
mean
modifi
jackson
score
tabl
particip
complet
modifi
jackson
score
ten
day
tabl
show
mean
sd
median
iqr
rang
modifi
jackson
score
baselin
day
group
mean
chang
modifi
jackson
score
baselin
greater
rhinothermi
group
control
group
hour
remain
greater
control
group
day
tabl
figur
show
plot
chang
baselin
modifi
jackson
score
total
particip
report
feel
lot
better
within
day
randomis
particip
rhinothermi
group
control
group
particip
two
particip
fill
modifi
jackson
score
day
felt
lot
better
therefor
estim
mcid
use
score
particip
rhinothermi
group
nine
control
group
recognis
posthoc
threshold
lot
better
correspond
estim
substanti
clinic
benefit
rather
mcid
estim
chang
repres
substanti
clinic
benefit
chang
baselin
modifi
jackson
score
best
sensit
specif
particip
state
felt
lot
better
unit
modifi
jackson
score
day
tabl
base
analysi
propos
unit
chang
modifi
jackson
score
substanti
clinic
benefit
threshold
instrument
differ
modifi
jackson
score
rhinothermi
group
control
group
greater
substanti
clinic
benefit
threshold
day
three
four
five
p
tabl
complet
resolut
symptom
denot
modifi
jackson
score
zero
occur
particip
within
day
randomis
particip
complet
modifi
jackson
score
day
rhinothermi
group
two
vitamin
c
group
hazard
ratio
ci
feel
lot
better
rhinothermi
compar
control
sd
modifi
jackson
score
day
base
pool
valu
test
ci
chang
baselin
modifi
jackson
score
ci
posit
nasal
swab
pcr
respiratori
viru
found
particip
organ
found
shown
tabl
human
rhinoviru
commonli
detect
viru
found
one
third
particip
evid
interact
treatment
differ
modifi
jackson
score
nasal
swab
posit
neg
time
point
valu
given
n
mean
total
use
myairvo
devic
hour
mean
sd
hour
per
day
eight
particip
use
myairvo
devic
day
seven
particip
use
less
day
day
myairvo
use
mean
sd
use
hour
per
day
particip
control
group
took
five
vitamin
c
tablet
per
protocol
adher
day
one
clinic
particip
use
flow
day
two
particip
kept
use
flow
rate
home
particip
use
reduc
flow
flow
use
particip
respect
day
three
four
five
mixtur
differ
flow
rate
use
mean
flow
rate
overal
around
toler
questionnair
result
myairvo
shown
tabl
devic
reason
simpl
connect
home
comfort
wear
accept
regard
amount
moistur
buildup
weight
nasal
interfac
also
score
favour
respect
eas
applic
found
moder
noisi
overal
particip
score
mean
sd
unit
scale
like
futur
use
like
unlik
first
studi
investig
rhinothermi
use
modifi
myairvo
devic
strength
includ
randomis
control
design
complet
followup
particip
particip
studi
recruit
primarili
social
media
result
generalis
peopl
commun
symptom
common
cold
three
main
limit
appli
result
firstli
studi
design
feasibl
studi
mean
although
modifi
jackson
score
prespecifi
efficaci
outcom
measur
formal
specifi
primari
outcom
measur
secondli
due
natur
intervent
unabl
blind
particip
investig
alloc
intervent
futur
studi
aim
replic
result
explor
option
sham
rhinothermi
final
small
sampl
size
mean
although
studi
found
benefit
new
treatment
result
rel
fragil
modifi
jackson
score
would
need
chang
small
number
particip
receiv
rhinothermi
intervent
match
control
group
conclus
differ
particip
use
myairvo
devic
two
hour
per
day
averag
throughout
day
treatment
period
hour
day
use
instruct
particip
use
devic
late
treatment
cours
symptom
improv
around
third
particip
reduc
flow
rate
suggest
give
particip
option
reduc
flow
initi
lower
start
flow
worthwhil
although
primari
outcom
studi
rhinothermi
modifi
myairvo
devic
reduc
common
cold
symptom
compar
treatment
lowdos
vitamin
c
differ
randomis
group
observ
within
hour
efficaci
singl
dose
regimen
session
two
three
day
period
may
enhanc
implement
clinic
practic
worth
studi
howev
altern
rhinothermi
regimen
need
assess
studi
find
suggest
regimen
use
feasibl
studi
also
use
futur
rct
studi
also
inform
term
like
number
particip
requir
rct
estim
chang
modifi
jackson
score
denot
substanti
contributorship
statement
jame
fingleton
princip
investig
studi
guarantor
studi
affirm
manuscript
honest
accur
transpar
account
studi
report
import
aspect
studi
omit
discrep
studi
plan
regist
explain
day
day
day
day
day
day
day
